PharmaTher's Latest Submission to the FDA
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a dedicated specialty pharmaceutical company, has recently made headlines following the U.S. Food and Drug Administration's (FDA) issuance of a complete response letter (CRL) regarding their ketamine Abbreviated New Drug Application. The CRL was communicated to PharmaTher on a specific date, with the agency requiring new and updated information on various aspects related to the drug.
Understanding the Complete Response Letter
The FDA's CRL outlined certain deficiencies categorized as minor. Unlike other responses which might indicate significant concerns, this classification allows PharmaTher the opportunity to promptly address and rectify the issues identified. The agency was notably reassured by the stability data of the ketamine batches, which have maintained stability for 18 months, comforting investors and stakeholders alike.
Adhering to Regulatory Standards
In response to this CRL, PharmaTher is partnering closely with its third-party manufacturing associates to ensure that all concerns raised by the FDA are adequately addressed. They are dedicated to compliance with the stringent manufacturing protocols established by the FDA. They have pledged to keep stakeholders informed about their timeline for responding to these requirements.
Addressing the Ketamine Shortage
One of the prominent missions of PharmaTher is to combat the ketamine shortage that has been prevalent in the United States. The ketamine is recognized as a fundamental medication for various applications, particularly in anesthesia and pain management. Its prolonged absence from the market has led to an increase in the availability of compounded ketamine products, which are not FDA-approved for psychiatric conditions.
Ketamine's Role in Mental Health Treatment
Recently, the FDA published warnings regarding the potential dangers associated with these non-approved compounded products, which have gained traction due to the ketamine shortage. This situation emphasizes the importance of having a reliable, FDA-approved version of ketamine accessible for patients needing treatment for mental health disorders.
The Path Forward for PharmaTher
PharmaTher has expressed its commitment to addressing these concerns and is eager to proceed with the necessary amendments categorized within the CRL as minor. Their approach demonstrates a proactive stance towards regulatory compliance, and their ongoing dialogue with the FDA signifies their intention to resolve these issues swiftly.
Exploring New Developments
The company is also focused on enhancing its ketamine product line through innovative research. With ketamine being listed on the World Health Organization’s Essential Medicines List, PharmaTher has the opportunity to not only meet the current demand but also expand its scope in treating various conditions beyond anesthesia and pain relief.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. is dedicated to the advancement and commercialization of KETARX™ (Ketamine) to address the unmet medical demands in various therapeutic areas, including anesthesia and mental health. The company holds a significant stake in Sairiyo Therapeutics Inc., which is engaged in developing a novel formulation of cepharanthine for medical countermeasures.
Company Contact Information
For any inquiries about PharmaTher, please reach out to:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Frequently Asked Questions
What is a Complete Response Letter (CRL)?
A CRL is a communication from the FDA indicating that an application cannot be approved in its current form due to identified deficiencies.
How is PharmaTher planning to address the CRL?
PharmaTher is collaborating with its manufacturing partners to rectify the minor deficiencies cited by the FDA and is preparing to submit necessary amendments.
What significance does ketamine hold in medicine?
Ketamine is critical for anesthesia and pain management and is part of treatment protocols for various mental health disorders.
Why is there a ketamine shortage?
The shortage stems from supply chain issues, which have led to increased unauthorized compounded ketamine products in the market.
What does PharmaTher aim to achieve with KETARX™?
PharmaTher aims to provide a reliable FDA-approved ketamine product to address the current shortage and to enhance treatment options for patients needing care.
